Adjusted versus xed doses of the low-molecular-weight heparin fragmin in the treatment of deep vein thrombosis. Thromb Haemost. 1994;71(6):698-702. 138. Laposata M, Green D, Van Cott EM, Barrowcliffe TW, GoodnightSH,SosolikRC.CollegeofAmericanPathologists 2012 American College of Chest Physicians by Kimberly Henricks on February 10, 2012 chestjournal.chestpubs.org Downloaded from www.chestpubs.org CHEST / 141 / 2 / FEBRUARY, 2012 SUPPLEMENT e41S with heparin, its fractions and fragments. Semin Thromb Hemost. 1985;11(2):176-189. 171. Wolzt M, Weltermann A, Nieszpaur-Los M, et al. Studies on the neutralizing effects of protamine on unfractionated and low molecular weight heparin (Fragmin) at the site of acti- vation of the coagulation system in man. Thromb Haemost. 1995;73(3):439-443. 172. Gatt A, van Veen JJ, Woolley AM, Kitchen S, Cooper P, Makris M. Thrombin generation assays are superior to tra- ditional tests in assessing anticoagulation reversal in vitro. Thromb Haemost. 2008;100(2):350-355. 173. Hirsh J, Levine MN. Low molecular weight heparin. Blood. 1992;79(1):1-17. 174. Crowther MA, Berry LR, Monagle PT, Chan AK. Mechanisms responsible for the failure of protamine to inactivate low-molecular-weight heparin. Br J Haematol. 2002;116(1):178-186. 175. Van Ryn-McKenna J, Cai L, Ofosu FA, Hirsh J, Buchanan MR. Neutralization of enoxaparine-induced bleeding by protamine sulfate. Thromb Haemost. 1990; 63(2):271-274. 176. Bang CJ, Berstad A, Talstad I. Incomplete reversal of enox- aparin-induced bleeding by protamine sulfate. Haemostasis. 1991;21(3):155-160. 177. Ng HJ, Koh LP, Lee LH. Successful control of postsur- gical bleeding by recombinant factor VIIa in a renal failure patient given low molecular weight heparin and aspirin. Ann Hematol. 2003;82(4):257-258. 178. Byun Y, Singh VK, Yang VC. Low molecular weight prot- amine: a potential nontoxic heparin antagonist. Thromb Res. 1999;94(1):53-61. 179. Wake eld TW, Andrews PC, Wrobleski SK, et al. Effective and less toxic reversal of low-molecular weight heparin anti- coagulation by a designer variant of protamine. J Vasc Surg. 1995;21(5):839-850. 180. 